Dr. Iliuk’s group focuses on discovery, development and validation of exosomal proteins and phosphoproteins as liquid biopsy biomarkers. He developed the procedures and technologies (including EVtrap) that enable complete recovery of exosomes for effective analysis of proteins and nucleic acids in plasma, urine and saliva. His group was the first to successfully demonstrate the utility of exosomal phosphoproteins for detection of cancer from plasma and urine. His company currently focuses on partnerships to develop novel biomarkers for cancer, AD, preeclampsia and other conditions. Internally, Tymora’s objective is to develop the first exosomal protein diagnostic test for urine-based detection of bladder cancer. Iliuk received a B.S. and M.S. in Chemistry from ENMU, and a Ph.D. in Biochemistry in 2011 at Purdue University. In 2010-2011 Iliuk co-founded Tymora Analytical with Dr. Andy Tao for dissemination of their technologies for proteomics and biomarker discovery.
Liquid Biopsy Showcase: Tymora Analytical Operations
Tymora Analytical provides diagnostic development, contract services and products for detection of active disease biomarkers directly from biofluids.
Exosome Phosphoproteomics For Non-Invasive Cancer Diagnostics
The presentation will focus on the novel procedure to capture and analyze exosomes from plasma and urine, that enables detection of cancer-activated proteins and phosphoproteins that were previously undetectable.